Update from Biogen
In a community statement, Biogen shared that the BRAVE Study, its global Phase 3 clinical trial evaluating the efficacy and safety of omaveloxolone in children ages 2 to 15 with FA, has completed enrollment ahead of schedule.
Read the full statement at the link below.
